Mechanisms of Platelet Aggregation by Murine Tumor Cell Sheddings

  • Gabriel J. Gasic
  • Tatiana B. Gasic
  • Gwendolyn J. Stewart
Part of the Developments in Oncology book series (DION, volume 22)


Cells from a variety of animal and human neoplasms can induce the aggregation of platelets in plasma (1–3). While the mechanism of this effect has not been fully elucidated preliminary evidence suggests that several mechanisms may exist. With human tumor cells platelet aggregation may be induced via mechanisms involving the leakage of tumor cell ADP (2, 4, 5; see also Chapters 11 and 12). In rodents aggregation may occur with both whole cells and cell sheddings. This suggests that the aggregating activity of intact cells is mediated by the spontaneous release of some subcellular component. We found that a mixture of membrane vesicles and cytoplasmic dense granules were shed (6). Normal cells are also capable of shedding a small amount of material which is much less active in platelet aggregation (6,7).


Platelet Aggregation Membrane Vesicle Platelet Rich Plasma Dense Granule Sucrose Density Gradient Centrifugation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gasic GJ, Gasic TB, Galanti N, Johnson T and Murphy S. Int. J. Cancer 11: 704–718, 1981.CrossRefGoogle Scholar
  2. 2.
    Gasic GJ, Koch PAG, Hsu B, Gasic TB and Niewiarowski S. Z. Krebsforch. 86: 263–277, 1976.CrossRefGoogle Scholar
  3. 3.
    Karpatkin S and Pearlstein E. Ann. Intern. Med. 95: 636–641, 1981.PubMedGoogle Scholar
  4. 4.
    Pearlstein E, Anbrogio C, Gasic G and Karpatkin S. Cancer Res. 41: 4535–4539, 1981.PubMedGoogle Scholar
  5. 5.
    Bastida E, Ordinas A, Giardina SL and Jamieson GA. Cancer Res. 42: 4348–4352, 1982.PubMedGoogle Scholar
  6. 6.
    Gasic GJ, Boettiger D, Catalfamo JL, Gasic TB and Stewart GJ. Cancer Res. 38: 2950–2955, 1978.PubMedGoogle Scholar
  7. 7.
    Pearlstein E, Cooper L and Karpatkin S. J. Lab. Clin. Med. 93: 332–344, 1979.Google Scholar
  8. 8.
    Gasic GJ, Catalfamo JL, Gasic TB and Avdalovic N. In: Malignancy and the Hemostatic System (Eds. Donati MB, Davidson JF and Garattini S), Raven Press, New York, pp. 27–35, 1981.Google Scholar
  9. 9.
    Cavanaugh PG, Sloane BF, Bajkowski A, Gasic GJ, Gasic TB and Honn KV. Clin. Exp. Metastasis (in press).Google Scholar
  10. 10.
    Gasic GJ, Gasic TB. In: Interaction of Platelets and Tumor Gells (Ed. Jainieson GA), Alan R. Liss, New York, pp. 429–443, 1982.Google Scholar
  11. 11.
    Hara Y, Steiner M and Baldini MG. Cancer Res. 40: 1217–1223, 1980.PubMedGoogle Scholar
  12. 12.
    Karpatkin S, Smerling A and Pearlstein E. J. Lab. Clin. Med. 95: 994–1001, 1980.Google Scholar
  13. 13.
    Gasic GJ, Gasic TB and Jimenez SA. Lab. Invest. 36: 413–419, 1977.PubMedGoogle Scholar
  14. 14.
    Stenflo, J. Adv. Enzymol. Itelat. Areas Mol. Biol. 46: 1–36, 1978.Google Scholar
  15. 15.
    Markwardt F. Methods Enzymol. 19: 924–932, 1970.CrossRefGoogle Scholar
  16. 16.
    Wasteson A, Glimelius B, Busch C, Westermark B, Hedlin C-H and Norling B. Thranb. Res. 1: 309–321, 1977.CrossRefGoogle Scholar
  17. 17.
    Oosta GM, Faverau LV, Beeler DL and Rosenberg RD. J. Biol. Chem. 257: 11249–11255, 1982.PubMedGoogle Scholar
  18. 18.
    Gordon SG and Cross BA. J. Clin. Invest. 67: 1665–1671, 1981.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Gabriel J. Gasic
  • Tatiana B. Gasic
  • Gwendolyn J. Stewart

There are no affiliations available

Personalised recommendations